EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS

Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14160%2F24%3A00139095" target="_blank" >RIV/00216224:14160/24:00139095 - isvavai.cz</a>
Výsledek na webu
<a href="https://www.webofscience.com/wos/woscc/full-record/WOS:001280297200001" target="_blank" >https://www.webofscience.com/wos/woscc/full-record/WOS:001280297200001</a>
DOI - Digital Object Identifier
—

Jazyk výsledku
angličtina
Název v původním jazyce
EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
Popis výsledku v původním jazyce
TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis. TAK-279 is a highly potent, selective, oral, allosteric TYK2 inhibitor shown to be clinically effective with an acceptable safety profile in a phase 2b trial in patients with moderate-to-severe psoriasis.¹ Objectives: To evaluate efficacy and safety of TAK-279 in patients with active PsA treated over 12 weeks.
Název v anglickém jazyce
EFFICACY AND SAFETY OF TAK-279, A SELECTIVE, ORAL TYK2 INHIBITOR, IN A RANDOMIZED, PLACEBO-CONTROLLED PHASE 2B TRIAL IN PSORIATIC ARTHRITIS
Popis výsledku anglicky
TYK2 mediates signaling by key cytokines involved in the pathogenesis of immune-mediated inflammatory diseases such as psoriatic arthritis (PsA) and psoriasis. TAK-279 is a highly potent, selective, oral, allosteric TYK2 inhibitor shown to be clinically effective with an acceptable safety profile in a phase 2b trial in patients with moderate-to-severe psoriasis.¹ Objectives: To evaluate efficacy and safety of TAK-279 in patients with active PsA treated over 12 weeks.

Projekt
—
Návaznosti
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění
2024
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Podobné výsledky(10)